BNCT(SH:688282)2023-04-25 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥8,269,302.52, a decrease of 88.03% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥10,979,278.13, down 22.82% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was -¥4,893,247.80, representing a decline of 135.54%[5]. - Basic earnings per share were ¥0.12, a decrease of 42.10% compared to the previous year[6]. - Total operating revenue for Q1 2023 was ¥8,269,302.52, a significant decrease from ¥69,089,734.59 in Q1 2022, representing a decline of approximately 88.0%[19]. - Total operating costs for Q1 2023 were ¥15,313,200.73, down from ¥50,382,919.19 in Q1 2022, indicating a reduction of about 69.6%[19]. - Net profit for Q1 2023 was ¥10,979,278.13, compared to ¥14,226,229.42 in Q1 2022, reflecting a decrease of approximately 22.8%[21]. - Basic and diluted earnings per share for Q1 2023 were both ¥0.12, down from ¥0.22 in Q1 2022, a decline of 45.5%[22]. - The company reported other income of ¥14,471,361.08 in Q1 2023, compared to ¥8,437.01 in Q1 2022, indicating a substantial increase[19]. Cash Flow and Assets - The net cash flow from operating activities was ¥9,844,689.31, with no applicable year-on-year comparison[5]. - Cash flow from operating activities for Q1 2023 was ¥9,844,689.31, a turnaround from a negative cash flow of -¥10,659,610.81 in Q1 2022[22]. - Cash flow from investing activities resulted in a net outflow of -¥150,836,468.61 in Q1 2023, compared to -¥907,293,924.79 in Q1 2022, showing a significant improvement[23]. - Cash and cash equivalents at the end of Q1 2023 totaled ¥267,266,184.12, down from ¥424,865,379.43 at the end of Q1 2022[23]. - The company's cash and cash equivalents decreased to CNY 267,266,184.12 from CNY 408,704,440.18, representing a decline of approximately 34.5%[15]. Research and Development - R&D investment totaled ¥6,354,765.47, an increase of 55.28% year-on-year, accounting for 76.85% of operating revenue[6][9]. - The company incurred research and development expenses of ¥6,354,765.47 in Q1 2023, up from ¥4,092,473.27 in Q1 2022, reflecting a growth of approximately 55.4%[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,738,120,513.41, a decrease of 0.99% from the end of the previous year[6]. - As of March 31, 2023, the company's total assets amounted to CNY 1,738,120,513.41, a decrease from CNY 1,755,520,914.06 at the end of 2022[16]. - The total current liabilities decreased to CNY 207,942,814.16 from CNY 236,258,572.76, reflecting a reduction of approximately 12.0%[17]. - The company's total equity increased to CNY 1,523,636,946.00 from CNY 1,512,657,667.87, showing a growth of about 0.7%[17]. - The company's accounts receivable slightly decreased to CNY 264,988,562.34 from CNY 269,085,170.89, a decline of approximately 1.6%[15]. - The inventory increased to CNY 47,488,362.85 from CNY 42,209,183.43, representing an increase of about 12.0%[15]. - The company's long-term equity investments were reported at CNY 2,000,000.00[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,846[11]. Future Outlook - The company has not provided any specific guidance or outlook for future performance in the available documents[14].